Your search history is turned on.
Date: April 23, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 5, 2024 NOTICE AND ACCESS NOTIFICATION TO SHAREHOLDERS You are receiving this notification as Crescita Therapeutics Inc. (the Corporation) has elected to use the notice and access system for delivery of meeting materials to its shareholders in respect of its annual general and special...
PROXY SOLICITED BY THE MANAGEMENT OF CRESCITA THERAPEUTICS INC. For use at the Annual General and Special Meeting of Shareholders to be held on Wednesday, June 5, 2024. The undersigned shareholder of CRESCITA THERAPEUTICS INC. (the Corporation) hereby appoints Serge Verreault, President and CEO of the Corporation, or, instead of him, ____________________________...
2023 Annual Report Managements Discussion and Analysis March 12, 2024 Basis of Presentation This Managements Discussion and Analysis of the financial position and results of operations (MD&A) is the responsibility of management and has been reviewed and approved by Crescitas board of directors (the Board of Directors). This MD&A ha...
Notice of Annual General and Special Meeting of Shareholders and Management Information Circular TO BE HELD WEDNESDAY, JUNE 5, 2024 AT 9:00 A.M. (ET) at 2805 PLACE LOUIS-R-RENAUD, LAVAL, QUBEC RECORD DATE: MONDAY, APRIL 8, 2024 PROXY CUT-OFF DATE AND TIME NO LATER THAN 5:00 P.M. (ET) ON MONDAY, JUNE 3, 2024 2 ...
NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General and Special Meeting of Shareholders (the Meeting) of CRESCITA THERAPEUTICS INC. (the Corporation or Crescita) will be held on Wednesday, June 5, 2024 at 9:00 a.m. (ET) at 2805 Place Louis-R-Renaud, Laval, Qubec for the following purposes: (...
Date: March 26, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
FORM 52-109F1 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Jose DaRocha, Chief Financial Officer of Crescita Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated...
FORM 52-109F1 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Serge Verreault, President and Chief Executive Officer of Crescita Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information ...
Date: March 26, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, DAROCHA, Jose, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
ANNUAL INFORMATION FORM FISCAL YEAR ENDED DECEMBER 31, 2023 March 20, 2024 i Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION ............................................. 1 CERTAIN REFERENCES .................................................................................